# A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma

> **NCT02748135** · PHASE1 · COMPLETED · sponsor: **Oncurious NV** · enrollment: 18 (actual)

## Conditions studied

- Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)

## Interventions

- **DRUG:** TB-403 20mg/kg
- **DRUG:** TB-403 50mg/kg
- **DRUG:** TB-403 100mg/kg
- **DRUG:** TB-403 175mg/kg

## Key facts

- **NCT ID:** NCT02748135
- **Lead sponsor:** Oncurious NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2020-10-06
- **Final completion:** 2020-10-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02748135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02748135, "A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02748135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*